NRP 2945

Drug Profile

NRP 2945

Alternative Names: NNZ 4945; NRP 2945

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Calzada; Neuren Pharmaceuticals
  • Developer Calzada; CuroNZ; Neuren Pharmaceuticals
  • Class Neuropeptides
  • Mechanism of Action Cell differentiation stimulants; CXCR4 receptor modulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Epilepsy
  • Preclinical Multiple sclerosis

Most Recent Events

  • 13 Apr 2017 NRP 2945 - CuroNZ is available for licensing as of 13 Apr 2017. http://www.curonz.com/
  • 13 Apr 2017 CuroNZ plans a phase II trial for Epilepsy (Second-line therapy or greater, In children)
  • 14 Mar 2017 Phase-I clinical trials in Epilepsy (In volunteers) in Australia (SC) (ACTRN12617000377336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top